Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...
Business Wire

Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients

SAINT LOUIS, Mo.--(BUSINESS WIRE)--Cofactor Genomics, the company bridging the precision medicine gap, today announced successful validation of the OncoPrism immunotherapy predictive diagnostic assay, ...
TechCrunch

Cofactor Genomics pulls in $18 million with the aim to save lives through RNA research

Cofactor Genomics has announced an $18 million Series A financing round led by Menlo Ventures, with participation from DCVC, Ascension Ventures, iSelect, Y Combinator, Wilson Sonsini Goodrich & Rosati ...